Placebo News and Research

RSS

George Mason trial: New pill aims to sustain weight loss after GLP-1s

GLP-1 medications like Ozempic and Wegovy have transformed obesity treatment, but maintaining weight loss after the medications stop remains a challenge.

9 Jan 2026

Real-time smartphone monitoring improves evaluation of insomnia treatment effectiveness

About one in nine adults suffer from chronic insomnia and its residual effects like drowsiness, cognitive issues, and irritability as well as increased health risks like diabetes and heart risks if left untreated.

8 Jan 2026

Arginine can modify plaque formation on teeth and protect against dental caries

New human clinical trial proves arginine, an amino acid, can modify plaque formation on teeth, thereby protecting against dental caries.

8 Jan 2026

Stopping weight loss drugs leads to rapid weight regain and health reversal

Stopping weight loss drugs is followed by weight regain and reversal of beneficial effects on heart and metabolic health markers such as high cholesterol and high blood pressure, finds a study published by The BMJ today.

7 Jan 2026

Single-dose oral cholera vaccine shows promising results in early clinical trial

Clinical trial shows promising results for PanChol, a single-dose oral vaccine aimed at the up to 4 million annual cholera cases worldwide.

7 Jan 2026

THC products provide small improvements in pain but carry side effects

A new systematic evidence review finds that cannabis products that carry relatively high levels of the psychoactive compound tetrahydrocannabinol, commonly known as THC, may provide short-term improvements in pain and function.

22 Dec 2025

Probiotic supplementation restores beneficial gut bacteria in breastfed infants

In recent years, scientists have learned that key beneficial infant gut bacteria Bifidobacterium infantis are disappearing from infants in high-resource areas such as the United States and Europe.

22 Dec 2025

Long-approved drug shows promise in slowing neuron loss in Alzheimer’s disease

Scientists at the University of Colorado Anschutz have discovered that while brain neuron changes, including cell loss, may begin in early life, a drug long-approved for other conditions might be repurposed to slow this damage, offering new hope for those with Alzheimer's disease (AD) and other cognition issues.

19 Dec 2025

Inside the FDA’s vaccine uproar

Six days after a senior FDA official sent a sweeping internal email claiming that covid vaccines had caused the deaths of "at least 10 children," 12 former FDA commissioners released an extraordinary warning in the Dec. 3 issue of the New England Journal of Medicine.

19 Dec 2025

High-dose rifampicin does not improve survival in tuberculosis meningitis

Each year, 11 million people worldwide develop tuberculosis, and about 1.4 million die from it. Meningitis occurs in 1–2% of patients and is the most severe complication of tuberculosis, arising when the bacteria reach the brain.

17 Dec 2025

Sitting harms blood vessel function, but cocoa flavanols can stop it

This study shows that cocoa flavanols can preserve endothelial function during sitting, suggesting dietary strategies to mitigate cardiovascular risks.

17 Dec 2025

Blood test identifies colon cancer patients who benefit from anti-inflammatory medication

A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery, according to new study in JAMA Oncology.

15 Dec 2025

Lipoic acid shows limited benefit in progressive multiple sclerosis

The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new research led by Oregon Health & Science University and the Portland VA Health Care System.

15 Dec 2025

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

12 Dec 2025

Varenicline helps young people quit nicotine vaping regardless of cannabis use

Adolescent and young adult nicotine vaping has become an urgent public health concern, as 2024 marked the first year that nicotine vaping was the most initiated drug.

12 Dec 2025

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding, were able to maintain safe platelet counts without serious bleeding episodes for at least one year.

9 Dec 2025

TXA reduces the need for blood transfusion in patients undergoing high-risk non-cardiac surgery

When hospitals were randomly assigned to treat patients undergoing higher-risk non-cardiac surgery with tranexamic acid (TXA) or a placebo, patients who received TXA needed significantly fewer blood transfusions and saw no increase in potentially life-threatening blood clots (thrombosis) after 90 days of follow-up, according to research presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

9 Dec 2025

Laughing gas shows fast antidepressant effects in early clinical trials

A systematic review and meta-analysis in eBioMedicine shows that nitrous oxide can rapidly reduce depressive symptoms within hours, particularly at higher doses, but effects are short-lived after single treatments. Repeated dosing appears to extend and strengthen antidepressant benefits, although the current evidence is based on small, early-phase trials with limited long-term safety data.

8 Dec 2025

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

In adults with stage IIIb–IV chronic kidney disease, the constipation drug lubiprostone did not reduce gut-derived uremic toxins but preserved creatinine-based kidney function over 24 weeks. The benefit was linked to microbiome remodeling, increased polyamine production, and improved mitochondrial function rather than toxin lowering.